

Values and Preferences Informing Treatment Decisions in Alzheimer’s Disease and Related Dementias: A Scoping Review Protocol

Jeong Eun Kim, PhD, RN¹
Amy Studer, MSN, MSLIS, AHIP²
Hyejin Kim, PhD, RN³
Jennifer Lingler, PhD, MA, CRNP, FAAN¹

1 University of California, Davis
Betty Irene Moore School of Nursing
Sacramento, CA, USA

2 University of California, Davis
Blaisdell Medical Library
Sacramento, CA, USA

3 Rush University
School of Nursing
Chicago, IL, USA

Contact: jkim19@health.ucdavis.edu

BACKGROUND

The emergence of amyloid-lowering therapies has increased the need for clinicians to engage patients and their families in complex discussions about treatment and prevention, including eligibility, potential risks, and anticipated benefits.

Shared decision-making places patients’ values and preferences at the center of healthcare decisions alongside the best available scientific evidence and ensure that individuals make informed healthcare decisions that align with what matters most to them.

Current resources focus on information delivery rather than addressing patients and families’ values, and there is limited understanding of how shared decision-making is represented in the literature in the context of anti-amyloid monoclonal antibody therapies.

Objective:

This scoping review will aim to :

- 1) synthesize the current evidence on the range of values, preferences, and decision-making needs of individuals with Alzheimer’s disease and related dementias (ADRD) and their families when making decisions related to anti-amyloid monoclonal antibody therapies for Alzheimer’s disease,
- 2) and examine how values and preferences are described and conceptualized.

METHODS

Inclusion criteria

- **Population:** Individuals with mild cognitive impairment or mild dementia, biomarker positive for Alzheimer’s disease who are eligible for or considering anti-amyloid monoclonal antibody therapies
- **Concept:** preferences and values related to decision-making for pursuing anti-amyloid monoclonal antibody therapies
- **Context:** anti-amyloid monoclonal antibody therapies for ADRD (e.g. Lecanemab, Donanemab)




Figure 1. Process for conducting scoping review

Critical Appraisal

- Quality assessment will be conducted using appropriate JBI critical appraisal tools based on study design
- Findings will inform interpretation of the evidence and not be used to exclude studies.

IMPLICATIONS OF FINDINGS

Findings will identify gaps in our current literature in the values and preferences of individuals and family members when considering disease modifying therapies for Alzheimer’s disease.

This review will inform future research aimed at understanding and supporting shared decision-making regarding anti-amyloid monoclonal antibody therapies.

